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Abstract
Objective: To review the effects of probiotics and prebiotics in clinical pediatric practice.
Sources: MEDLINE was searched, especially for articles that addressed their practical application, in the form of
reviews, clinical trials and meta-analyses. Articles that had already been analyzed by the authors were also included.
Summary of the findings: Scientific literature on probiotics and prebiotics has remarkably increased in the last 10
years. Their mechanisms of action have been experimentally investigated. Studies indicate that probiotics can act by
competing with pathogens, modifying the intestinal environment by reduction in pH, as a result of fermentation products,
interacting and modulating local and systemic inflammatory and immune response, among others. Clinical trials and
meta-analyses show that probiotics seem to contribute towards the prevention of acute diarrhea and of antibiotic-
associated diarrhea, in addition to shortening the duration of acute diarrhea. However, the data are inconsistent and there
are no studies confirming their efficacy in terms of cost-benefit ratio. Preliminary studies show that probiotics in early
life can reduce the occurrence of atopic dermatitis. The addition of prebiotics to infant formulas is associated with the
change in the profile of the intestinal microbiota compared to infants fed milk formulas without prebiotics.
Conclusions: Evidence indicates that new studies should be carried out about probiotics, prebiotics and symbiotics.
The specific clinical effects that each probiotic or prebiotic may cause must be considered.
J Pediatr (Rio J). 2006;82(5 Suppl):S189-97: Prebiotics, probiotics, symbiotics, lactobacillus, bifidobacteria,
diarrhea.
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Introduction
Modern society, in industrialized countries, has a
different disease profile today than it used to have
decades ago, when infectious diseases prevailed. Now,
there has been a progressive increase in the occurrence of
allergic, autoimmune and chronic inflammatory diseases.
The same has occurred in developing countries, where this
process may currently coexist with infectious diseases.1
This phenomenon, according to some evidence, seems
to result from changes in the western society, such as the
reduced contact of children with microorganisms, attained
by better hygiene and vaccination conditions and by
changes in eating habits which, together, determine
changes to the intestinal microbiota (intestinal flora).1
This process is part of the so-called hygiene hypothesis.
Information about the importance of the intestinal flora as
an active mechanism for the control of infectious processes
and for the modulation of immune response has encouraged
the search for treatment and prevention measures against
diseases based on the maintenance of the ideal intestinal
flora.1 A way to achieve this effect is the observation of the
characteristics of the normal intestinal flora and of several
attempts to restructure it, either by introducing
microorganisms that provide health benefits, or substances
that help their growth.1
Historically, fermented milks have been used by humans
for over 10,000 years.2 This is one of the oldest methods
for food preservation. With regard to their benefits to
human health, Metchnikoffs observations, made in the
early 20th century, are noteworthy, since he related the
consumption of fermented milk to the longer longevity of
Bulgarian peasants. In the 1930s, Shirota, in Japan,
isolated a lactobacillus species that has been used in the
production of a fermented milk, commercialized for several
decades, also in Brazil. Both lactobacilli and bifidobacteria
were initially identified by Moro and Tissier, respectively,
in the stools of infants fed human milk, at the turn of the
19th century.2-4
The use of the term probiotic for living organisms dates
back to 1989, when they were regarded as a supplement
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Table 1 - Number of articles indexed in MEDLINE between 1996 and 2005, using the keywords probiotic or
probiotics and prebiotic or prebiotics
Probiotic Prebiotic
Total Randomized Meta- Total Randomized Meta-
controlled analysis controlled analysis
trial trial
1996 30 3 0 24 0 0
1997 51 8 0 43 0 0
1998 118 4 0 54 0 0
1999 162 9 0 54 1 0
2000 197 18 1 35 1 0
2001 291 16 0 84 2 0
2002 404 30 4 116 4 0
2003 422 33 0 102 4 0
2004 508 45 0 128 6 0
2005 565 66 4 144 19 1
Total 2,748 232 9 784 37 1
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of living microorganisms that bring a health benefit by
improving the balance of the intestinal microbiota.3 In
2002, this concept was corroborated in a meeting of
experts held by the Food and Agriculture Organization
(FAO) and by the World Health Organization (WHO).5
On the other hand, prebiotics are defined as substances
which, when ingested, are not digested and taken up by
the small intestine, and that selectively stimulate a
bacterium or group of bacteria (e.g.: bifidobacteria) when
they reach the colon, bringing health benefits to the host.3
Symbiotics are defined as products that contain both
prebiotics and probiotics.3
The number of articles about probiotics and prebiotics
indexed in MEDLINE between 1996 and 2005 has
significantly increased. Table 1 shows the number of
published articles that contained the words probiotic(s)
and prebiotic(s). The annual increase in the number of
articles denotes the growing scientific interest they have
aroused to the health science literature. When we add the
keyword randomized clinical trial to the search, as
publication type, the number of articles falls drastically,
corresponding to 8.4% (232/2748) of articles on probiotics
and to 4.7% (37/784) of those on prebiotics. When the
word meta-analysis is used for the search, as publication
type, the number of publications is extremely low. Given
that randomized clinical trials represent the studies that
assess the efficacy of a given intervention, we may see
that there exists scant evidence regarding the use of
probiotics and prebiotics before a strong and definitive
position can be taken about their efficacy.
The available literature shows that there is a logical
theoretical basis for the mechanism of action of prebiotics
and probiotics. Moreover, some clinical trials have confirmed
their efficacy. There is a large potential for the use of
prebiotics and probiotics in several fields of human health,
including infections, allergies, inflammations and
neoplasms.6 However, it is very unlikely that a single
probiotic may have health benefits on such a wide range
of pathological processes.6
Scientifically speaking, probiotics and prebiotics are
incontestably a fascinating field of investigation and
research. They have the digestive tube, more specifically
the intestinal microbiota, as the place for their action,
considering also that the gastrointestinal tract can be the
site where several immune and inflammatory processes
commence. It should be borne in mind that probiotics can
potentially cause systemic effects, i.e., their effects can go
beyond the gastrointestinal tract.
Thus, the composition of the intestinal microbiota and
the effects of prebiotics and probiotics on the development
and maintenance of the intestinal microbiota regarded as
healthy are key to understanding the action of probiotics
and prebiotics. The major probiotics include the following:7,8
Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus
plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus,
Lactobacillus paracasei, Bifidobacterium bifidum,
Bifidobacterium breve, Bifidobacterium infantis,
Bifidobacterium lactis, Bifidobacterium longum,
Bifidobacterium adolescentis, Saccharomyces bourlardii,
and Propionibacterium freudenreichii.
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In the present article, we are going to briefly address
the following topics: 1. intestinal microbiota; 2. definition
of probiotics; 3. mechanisms of action of probiotics; 4.
probiotics and diarrhea; 5. probiotics and allergy; 6. safe
use of probiotics; 7. prebiotics in pediatrics and 8. final
remarks.
Source of data
To obtain the information included in the topics
mentioned above, we searched MEDLINE for articles,
especially clinical trials and meta-analyses and review
articles related to pediatrics. Articles that had been
previously analyzed by the authors were also used.
Therefore, we may say that the selected articles constituted
a convenience sample. A systematic review was not
carried out due to the vast extension of the topic addressed
in this article.
Intestinal microbiota
The intestine of a fetus is sterile. The digestive tube of
an infant born by vaginal delivery is initially colonized by
the vaginal and fecal flora of his/her mother. On the other
hand, infants born by C-section are colonized by
environmental bacteria. In addition to the type of delivery,
the type of feeding, natural or artificial breastfeeding, is
very important in determining the intestinal microbiota of
an infant. Natural breastfeeding provides an intestinal
microbiota predominantly (> 90%) constituted of
bifidobacteria and lactobacilli. In infants who are artificially
breastfed, these bacteria correspond to 40 to 60% of the
microbiota, where clostridia, staphylococci and bacteroides
are also found.1,3,7,8
In the digestive tube, there are marked differences in
the amount and in the species that make up the intestinal
microbiota. The stomach is practically sterile (except in
case of Helicobacter pylori infection). The proximal small
intestine contains up to 104 bacteria/mL, most of them
from the oropharynx and also those that survived the
effect of gastric acidity. In the colon, however, the amount
of bacteria is much larger, nearly 1012 bacteria per gram
of feces.
Once established, around the 18th to 24th month of
life, an individuals microbiota tends to be stable throughout
the lifetime. It includes 400 to 1,000 bacterial species, of
which 30 to 40 prevail. Approximately 97% of the species
are anaerobic and 3% are facultative anaerobic. An
intestinal microbiota with large participation of
bifidobacteria and lactobacilli is regarded as healthy.1,3,7
In individuals with an already established microbiota,
the influence of probiotics is usually restricted to the
period in which they are used. Thus, in order for these
individuals to keep the desired change in their intestinal
microbiota, they should ingest these microorganisms
continually and indefinitely.1
In children, especially when the intention is to use
probiotics for the prevention of certain diseases, the
intervention should be made during the establishment of
the infants intestinal microbiota, so that they become part
of the hosts definitive microbiota.1,9 The particularities of
the microbiota of an exclusively breastfed infant are
probably related to the advantages of natural breastfeeding
over artificial breastfeeding, such as the lower risk for
allergic diseases.
Table 2 shows the basic composition of human intestinal
microbiota.
Probiotics in pediatrics
Although the use of probiotics has been widespread in
the general population, only a few health benefits have
been actually confirmed by well-designed trials, which
allow for definitive conclusions.8 The definition of probiotics
is problematic to begin with. It should be properly
understood so that the effects of probiotics on human
health can be better determined.
Definition
The term probiotics was initially introduced in medical
literature by Lilly & Stillwell in 1965.10 Although many
definitions have already been proposed, we currently use
the one suggested by the meeting of FAO/WHO experts,
held in 2002: probiotics are living organisms, which when
administered in adequate amounts, confer a health benefit
on the host.5 According to this definition, we note that two
aspects are underscored: organisms must be living and in
adequate amounts. These two aspects exclude several
products referred to as probiotics.
The current definition has been criticized by some. New
studies indicate that bacterial products and even bacterial
DNA can exert benefits on health in specific situations.
New research into this matter should be undertaken and,
as scientific evidence is provided, the current definition
can then be adapted.
Some criteria are used for the definition of a
microorganism as probiotic:11
 human origin;
 nonpathogenic;
 resistance to processing;
 stability to acid and biliary secretion;
 adherence to the epithelial cell;
 capacity to persist in the gastrointestinal tract;
 capacity to influence local metabolic activity.
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Predominant genera of bacteria (colony-forming units /mL or /g)
Stomach and duodenum Jejunum and ileum Colon
101 - 103 104 - 108 1010 - 1012
Lactobacilli Lactobacilli Bacteroides
Streptococci Enterobacteria Bifidobacteria
Yeasts Streptococci  Streptococci
Bacteroides Fusobacteria
Bifidobacteria Enterobacteria
Fusobacteria Clostridium
Veilonella
Lactobacilli
Proteus
Staphylococci
Pseudomonas
Yeasts
Protozoa
Table 2 - Bacterial microbiota (flora) in human digestive tube
Adapted from Holzapfel et al.9
The major bacterial microorganisms regarded as
probiotic are those of the genera Lactobacillus and
Bifidobacterium, in addition to Escherichia, Enterococcus
and Bacillus. The fungus Saccaromyces boulardii has also
been considered to be probiotic. Other microorganisms
frequently added to infant feeding, such as Lactobacillus
bulgaricus and Streptococcus thermophilus are not
regarded as probiotic, since they do not meet the criteria
mentioned above. Despite this restriction, many
researchers regard them as probiotic, since they confer
benefits on human health.8
With regard to the adequate amounts for health
benefits, a dose of 5 billion colony-forming units a day
(5x109 CFU/day) has been recommended, for at least 5
days. Although this is the recommended dose, studies
assessing therapeutic effects recommend variable doses
from 106 to 109 CFU.12
Mode of action
The precise mechanisms of action of probiotics have
not yet been fully established.1,3,8,13 According to its own
definition, a probiotic should be viable at the time of
consumption. After ingestion, it should keep its viability
after coming in contact with gastric acid and bile salts. In
addition to overcoming this chemical barrier, probiotics
should adhere to the intestinal surface where they perform
their functions, competing with pathogenic agents and
modulating the hosts inflammatory and immune responses.
It should be highlighted that probiotics do not multiply
quickly, and so they are not permanent colonizers of the
digestive tube.13
Probiotic microorganisms positively change the
intestinal flora, inhibit the growth of pathogenic bacteria,
promote adequate digestion, stimulate the local immune
function and increase resistance to infection.
Change in intraluminal pH
Lactobacilli and bifidobacteria help maintain a healthy
balance of the intestinal flora by producing organic
compounds from fermentation, with formation of lactic
acid, hydrogen peroxide and acetic acid, which increase
acidity in the intestine, thus inhibiting the proliferation of
bacteria with potential damage to the intestinal epithelium.3
Production of substances with antimicrobial
activity
Bacteria regarded as probiotic also produce substances
known as bacteriocins, metabolically active proteins, which
help destroy undesirable microorganisms. Several
bacteriocins have already been described, including a low-
molecular weight substance, reuterin, produced by L.
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reuteri. Both lactobacilli and bifidobacteria are able to
produce these elements.3 Also interesting is that
Lactobacillus rhamnosus GG, in addition to producing
bacteriocins, also produces a biosurfactant, which helps
its own survival.
Competition for nutrients
This action is extremely important due to the fact
that the availability of nutrients is a limiting factor for
bacterial growth. One of the limiting factors for bacterial
growth in the intestinal lumen is the availability of
nutrients. Competition is fiercer in the distal colon,
where there is a smaller amount of food residues,
compared to the proximal colon and small intestine.
Therefore, the increase in the number of lactobacilli and
bifidobacteria would not allow the proliferation of
pathogenic bacteria.1-3
Competition for intestinal receptors for
adherence
One of the factors responsible for the action of
pathogenic bacteria in the gastrointestinal tract refers
to their capacity to adhere to specific receptors found in
the intestinal mucosa. One of the actions attributed to
probiotics, mainly to lactobacilli, is their capacity to
adhere to these receptors, not being eliminated by
peristalsis and preventing pathogenic bacteria such as
Salmonella typhimurium, Yersinia enterocolitica and
Escherichia coli from producing their enteropathogenic
effect.1-3 For instance, Lactobacillus plantarum
synthesizes adhesins for intestinal receptors that contain
mannose. Therefore, they compete with Escherichia
coli, which needs to bind to intestinal cells through these
receptors in order to exert its pathogenic activity.13
Immunomodulatory effect
The intestine is the largest lymphoid organ in the
human body and is an important setting for immune
reactions, including the presence of antibodies, such as
secretory immunoglobulin A and several immunocompetent
cells dispersed in the lamina propria and epithelium or
organized into well-defined structures, which play a key
role in antigenic presentation and development of immune
response to microorganisms and dietary proteins.
The immune effects of probiotics that have been
observed include increase in gamma-interferon in
patients with cows milk allergy and atopic dermatitis,
probably due to the deviation of immune response to a
TH1 profile.14 Thus, the presence of these agents in the
gastrointestinal tract can help with the development of
a tolerogenic response.
CD34+ hematopoietic precursor cells have been
detected in large numbers in the peripheral blood of atopic
patients. A study showed a reduction in these cells, in
addition to clinical resolution of symptoms in these patients,
after the use of probiotics.15
Recovery of intestinal permeability
Some lactobacilli may have some effect on the
expression of the mucin gene, stimulating the production
of mucus in the intestinal mucosa and contributing to the
efficiency of the barrier function of the intestinal mucosa.16
Gastrointestinal tract protein synthesis
Both lactobacilli and bifidobacteria are capable to
induce the synthesis of proteins with allergenic potential
in the gastrointestinal tract. This process can contribute to
the reduction of protein allergenicity, minimizing the risk
for food allergy.
Use of probiotics in clinical practice
Probiotics have been used in several interesting
situations in pediatric practice, but here, only those of
great importance and with potential use in clinical practice
will be discussed.
Probiotics and diarrhea
In Brazil and in other regions around the world, infant
mortality due to acute and persistent infectious diarrhea,
malnutrition, and dehydration among children younger
than 5 years has decreased in the last decades. This can
be ascribed to the wider availability of treated water,
longer duration of natural breastfeeding, widespread use
of oral rehydration therapy, better information and
availability of special formulas for the feeding of
malnourished infants with severe diarrhea, among other
factors. However, since the beginning of the last century,
there has been some interest in using probiotics for the
prevention and treatment of diarrhea. In the current
context, probiotics aimed for this purpose should be
regarded as adjuvant measures widely accepted as
efficient in the control and treatment of diarrhea and its
consequences.
The role of probiotics in the prevention and treatment
of diarrhea can be analyzed according to three perspectives:
 treatment of acute diarrhea;
 prevention of diarrhea;
 prevention of antibiotic-associated diarrhea.
The role of probiotics in the treatment of acute diarrhea
was analyzed in a meta-analysis published in 2001,17
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including seven double-blind, placebo-controlled,
randomized clinical trials, in which 416 patients were
assessed. Lactobacillus rhamnousus GG was used in three
of seven studies, Lactobacillus reuteri in two,
Saccharomyces boulardii in one and Lactobacillus
acidophilus in one study. The final result of the assessment
showed that patients treated with probiotics were 2.5
times less likely to have diarrhea for more than 3 days
after intervention than those who received placebo. With
regard to the duration of diarrhea immediately after
intervention, patients treated with probiotics showed, on
average, duration of diarrhea 18.2 hours shorter than the
controls. Considering only younger children with rotavirus
infection, this value corresponded to 24.8 hours, i.e.,
diarrhea lasted, on average, approximately one less day.
After 2001, clinical trials were published, which assessed
the efficiency of probiotics in the treatment of acute
diarrhea in children. In Denmark, 69 children aged 6 and
36 months hospitalized due to acute diarrhea were
investigated.18 Although hospitalized, none of the patients
was dehydrated. Rotavirus was identified in 66.7% of
patients. The intervention group received Lactobacillus
reuteri and Lactobacillus rhamnosus whereas the control
group received placebo (both for 5 days). Duration of
diarrhea immediately after intervention amounted to
81.5–37.3 hours in the intervention group and to
101.1–47.6 hours in the control group. However, no
statistical significance was observed (p = 0.07). On the
other hand, when only the patients included in the study
with previous duration of diarrhea less than 60 hours were
considered, the mean duration of diarrhea in 10 children
who received probiotics was lower (p = 0.03) than in 18
(79.6–44.0 hours) who received placebo (129.7–23.4
hours). The authors concluded that the effect of probiotics
was more pronounced when they were used in the initial
phase of the diarrheic process.18
In Brazil, a study including 124 children was carried out
to assess the effect of Lactobacillus GG on the reduction
of fecal losses in children with severe acute diarrhea
associated with dehydration (moderate or severe in over
90% of patients).19 The mean duration of diarrhea right
after the intervention was similar (p = 0.59), 38.3–3.8
and 39.1–4.6 hours, respectively, in the groups that
received probiotic and placebo. In addition, fecal losses
varied considerably in both groups, with similar medians
(p = 0.81), 67.7 and 56.1 mL/kg, respectively, in the
probiotic and placebo groups.19
A study conducted in Bangladesh assessed the effect
of Lactobacillus paracasei in 230 male infants aged 6 to 24
months and with diarrhea for less than 2 days. The study
showed that the use of probiotics was associated with a
statistically significant reduction in the following parameters
of patients with nonrotavirus diarrhea: cumulative fecal
loss, number of bowel movements, intake of oral
rehydration solution and proportion of children whose
diarrhea resolved on the sixth day of intervention. On the
other hand, no favorable effect was observed in infants
with rotavirus diarrhea.20
The role of probiotics in the prevention of diarrhea was
assessed by studies carried out with hospitalized infants or
in the community. Saavedra, in 1994, published the
results of a study that included 54 hospitalized infants
aged 5 to 24 months followed up for 17 months.21 The
infants fed milk formula containing probiotics (B. bifidus
and S. thermophilus) had a lower incidence of diarrhea
(7.0%) than those in the control group (31%).21 However,
a study conducted in the outskirts of a Peruvian town,
using Lactobacillus GG or placebo in 204 infants, did not
reveal any reduction in the duration of diarrheal episodes,
but showed some advantage for infants who were not
naturally breastfed.22 The use of probiotics in the prevention
of acute diarrhea was assessed in a meta-analysis
published in 2006.23 Nevertheless, only nine out of 28
studies included in the meta-analysis referred to infectious
diarrhea (the remaining articles were about antibiotic-
associated diarrhea and travelers diarrhea). The articles
on presumably infectious diarrhea showed a statistically
significant reduction (34%) in the risk for diarrhea.23
In the literature, there is a larger number of studies on
the prevention of antibiotic-associated diarrhea. A
pioneering study in this field was carried out by Vanderhoof
et al.24 The authors assessed 188 children who had
received antibiotics for the treatment of respiratory
infections combined with Lactobacillus GG or placebo.
There was a statistically significant reduction in the
occurrence of diarrhea in the probiotic group (relative
risk = 0.28 with a 95%CI between 0.13 and 0.62). A
Brazilian study, carried out by Correa et al., assessed the
effect of a milk formula with (Bifidobacterium lactis and
Streptococcus thermophilus) or without probiotics, in the
prevention of antibiotic-associated diarrhea in 157 children
aged 6 to 36 months who had received antibiotic therapy
against respiratory disorders.25 The percentage of children
who developed diarrhea on the  subsequent 30 days after
the implementation of antibiotic therapy corresponded to
16.3% in the group that received the milk formula with
probiotics, and to 31.2% in the control group, with a
statistically significant reduction. The prevention of
antibiotic-associated diarrhea with the use of probiotics
was assessed in four meta-analyses, two of them published
in 200226,27 and the other ones in June23 and August
2006.28 Those published in 2002 showed a relative risk of
0.37 and 0.40, with similar 95%CI, with the upper
confidence limit less than 1.0. Therefore, both showed
that the use of probiotics reduced the risk of antibiotic-
associated diarrhea by approximately 2.5 times.26,27 In
the studies published in 2006, which included a larger
number of clinical trials, these values were confirmed
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(0.43 with a confidence interval of 0.20 and 0.75 and 0.48
with a confidence interval of 0.35 and 0.65).23,28 In one
of these meta-analyses, which assessed six clinical trials
carried out exclusively with children, the intention-to-
treat principle was also evaluated.28 In this evaluation,
there was no advantage in the use of probiotics for the
prevention of diarrhea (relative risk = 1.0 with a confidence
interval of 0.62 and 1.61). Considering the subgroup of
four studies in which more than 5 billion colony-forming
units a day of probiotic (Lactobacillus GG, Saccharomyces
boulardi or L. sporogens) were given, there was stronger
evidence of protection, characterized by lower relative
risk and narrower confidence intervals.28
Probiotics and allergic diseases
Changes in the lifestyle of the population, especially in
the western world, with better hygiene conditions, also
reduced early contact with microorganisms, which may
have produced a reduction in the TH1 response to the
detriment of immune TH2 response, characteristic of
allergic processes.29 A proof of that is that children from
families that adopt an anthroposophic lifestyle, with
restricted use of antibiotics and vaccines and an organic
diet, show lower incidence of allergic processes, in addition
to having an intestinal microbiota rich in lactobacilli and
bifidobacteria.30 Most studies on the use of probiotics
have assessed patients with atopic eczema. Majamaa &
Isolauri assessed children with atopic eczema and cows
milk allergy and found health benefits with the use of L.
rhamnosus GG.31 Another study carried out in Finland
compared whether the use of one probiotic, four probiotics
or placebo had an additional effect on conventional
treatment of atopic dermatitis in infants.32 Topic treatment
included hydrocortisone and moisturizer, and cows milk
and derivatives were withdrawn from the diet, being
replaced by protein hydrolysate. It was a double-blind,
randomized trial that assessed 230 infants. The group that
received only one probiotic had an advantage over the
other two groups when an IgE-mediated mechanism was
identified. Surprisingly, the use of four probiotics yielded
similar results to those obtained with the placebo.
As far as respiratory allergy is concerned, two double-
blind, randomized controlled trials assessed the effects of
using lactobacilli in allergic patients.33,34 One of the
studies assessed the use of Lactobacillus acidophilus in
adults with moderate asthma and showed reduction in the
number of eosinophils and increase in gamma-interferon,
but without any changes in clinical parameters.33 Another
study assessed adolescents with pollen allergy and used
Lactobacillus rhamnosus GG without finding any health
benefits.34
With regard to the role of probiotics in the prevention
of early atopic disease, a study assessed the use of
Lactobacillus GG in pregnant women at the end of their
gestational period and in the first months of life of those
infants who had family history of atopic disease.9 At the
age of 2 years, the proportion of infants with atopic
dermatitis was lower among those who had received
Lactobacillus GG than among those who received placebo;
however, the increase in IgE levels, of specific
immunoglobulins and of positive skin puncture test results
was similar in both groups.9 The same infants who
participated in this study were reassessed at the age of 4
years and the protective effect against atopic dermatitis
persisted.35
Experimental studies have been carried out on the
effect of probiotics in animal models, suggesting that
the use of probiotics may help with the induction of oral
tolerance, preventing the TH2 response. So far, it is
necessary to better assess the effects of probiotics for
the control and/or prevention of allergic disease, since
experimental studies suggest that specific strains of
probiotics may act upon the intestinal mucosa with
potential modulation of the allergic response.36
Safe use of probiotics
This is a crucial issue  evaluating the potential use of
probiotics in pediatric patients. Studies have shown that
the use of probiotics in healthy individuals does not
increase the risk of bacterial diseases. Even in
immunosuppressed patients, this risk is seemingly low,
although 89 cases of bacteremia induced by lactobacilli
have been reported, usually associated with previous
severe comorbidities.37
Conclusion
Only some strains of probiotics have been included in
studies with rigorous scientific methodology. The findings
of these studies might probably not be applied to other
strains, since the effects may be strain-specific. New
information is necessary about the mechanism of action of
probiotics so that their therapeutic potential can be
explored. Currently, the most thriving use of probiotics
concerns diarrheas and, although some studies show
improvement of atopic eczema, these data need to be
corroborated. Further studies are necessary to confirm
the efficacy and safety of probiotics in the pediatric
population.
Prebiotics in pediatrics
According to the data shown in Table 1, the number
of articles related to prebiotics is quite smaller than the
publications on probiotics.
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in human milk. The bifidogenic effect of human milk,
known since the 1920s, was related to human milk
oligosaccharides in the 1950s.7 However, the composition
of human milk oligosaccharides is not the same for all
breastfeeding mothers. Thus, because of the qualitative
and quantitative variability of human milk oligosaccharides,
there may be differences in the infants intestinal
microbiota.7
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Final remarks
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Prebiotics, probiotics and symbiotics will certainly be
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